Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

ABSTRACT:

Background

Factor (F) XI deficiency is associated with increased bleeding risk in some individuals. Neither FXI levels nor clinical clotting assays predict the bleeding risk. Compared with controls, FXI-deficient bleeders have reduced clot formation, decreased fibrin network density, and increased susceptibility to fibrinolysis. Tissue factor pathway inhibitor (TFPI) was recently implicated as a modifying factor in individuals with bleeding of unknown cause.

Objectives

To determine the potential of TFPI in modifying the bleeding risk in FXI-deficient individuals.

Methods

The effects of TFPI on thrombin generation and clot formation, structure, and fibrinolysis in FXI-deficient plasma were measured in vitro in the absence or presence of inhibitory anti-TFPI antibody or

SUBMITTER: Reitsma SE 

PROVIDER: S-EPMC10111213 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature